# Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

> **NCT01084005** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 241 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** linagliptin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01084005
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-06
- **Final completion:** —
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2014-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01084005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01084005, "Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01084005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*